2353 Data from a phase Ib/II trial of the oral c-Met inhibitor tepotinib (MSC2156119J) as first-line therapy in Asian patients with advanced hepatocellular carcinoma
2015 ◽
Vol 51
◽
pp. S452-S453
◽
Keyword(s):
Phase Ib
◽